2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications

From December 31st, 2019, a novel highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide, reaching at present the dimension of a pandemic. In addition to damaging the lungs, SARS-CoV-2 may also damage the heart and this is corroborated by th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luigi Cappannoli, Roberto Scacciavillani, Giulia Iannaccone, Gianluca Anastasia, Federico Di Giusto, Valentina Loria, Nadia Aspromonte
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	COVID-19 Cardiovascular Angiotensin converting enzyme 2 Angiotensin converting enzyme inhibitors Angiotensin-II receptor blockers Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ee1065e9e7ef4c3dae9e5b007d6c215f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee1065e9e7ef4c3dae9e5b007d6c215f
record_format	dspace
spelling	oai:doaj.org-article:ee1065e9e7ef4c3dae9e5b007d6c215f2021-12-02T14:22:06Z2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications2095-882X10.1016/j.cdtm.2020.06.002https://doaj.org/article/ee1065e9e7ef4c3dae9e5b007d6c215f2020-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X2030061Xhttps://doaj.org/toc/2095-882XFrom December 31st, 2019, a novel highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide, reaching at present the dimension of a pandemic. In addition to damaging the lungs, SARS-CoV-2 may also damage the heart and this is corroborated by the evidence that cardiovascular comorbidities are associated with a higher mortality and poor clinical outcomes in patient infected by the virus. During the infection myocardial injury, myocarditis and arrhythmias have also been reported, but the pathophysiological mechanisms of these complications are yet to be understood. Great attention is also being posed on the potential beneficial/harmful role of angiotensin converting enzyme (ACE) inhibitors, as far as the virus binds to ACE2 to infect cells, but evidences lack. Furthermore, SARS-CoV-2 can also affect the aspect of acute coronary syndromes, not only because these two distinct pathological entities share pathogenic aspects (such as the systemic inflammatory state and cytokine release), but also and above all for the consequences that the need to contain the infection has on the management of cardiological urgencies. The aim of this review was therefore to summarize the relationship between the virus and the cardiovascular system.Luigi CappannoliRoberto ScacciavillaniGiulia IannacconeGianluca AnastasiaFederico Di GiustoValentina LoriaNadia AspromonteKeAi Communications Co., Ltd.articleCOVID-19CardiovascularAngiotensin converting enzyme 2Angiotensin converting enzyme inhibitorsAngiotensin-II receptor blockersMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 6, Iss 4, Pp 246-250 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 Cardiovascular Angiotensin converting enzyme 2 Angiotensin converting enzyme inhibitors Angiotensin-II receptor blockers Medicine (General) R5-920
spellingShingle	COVID-19 Cardiovascular Angiotensin converting enzyme 2 Angiotensin converting enzyme inhibitors Angiotensin-II receptor blockers Medicine (General) R5-920 Luigi Cappannoli Roberto Scacciavillani Giulia Iannaccone Gianluca Anastasia Federico Di Giusto Valentina Loria Nadia Aspromonte 2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
description	From December 31st, 2019, a novel highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide, reaching at present the dimension of a pandemic. In addition to damaging the lungs, SARS-CoV-2 may also damage the heart and this is corroborated by the evidence that cardiovascular comorbidities are associated with a higher mortality and poor clinical outcomes in patient infected by the virus. During the infection myocardial injury, myocarditis and arrhythmias have also been reported, but the pathophysiological mechanisms of these complications are yet to be understood. Great attention is also being posed on the potential beneficial/harmful role of angiotensin converting enzyme (ACE) inhibitors, as far as the virus binds to ACE2 to infect cells, but evidences lack. Furthermore, SARS-CoV-2 can also affect the aspect of acute coronary syndromes, not only because these two distinct pathological entities share pathogenic aspects (such as the systemic inflammatory state and cytokine release), but also and above all for the consequences that the need to contain the infection has on the management of cardiological urgencies. The aim of this review was therefore to summarize the relationship between the virus and the cardiovascular system.
format	article
author	Luigi Cappannoli Roberto Scacciavillani Giulia Iannaccone Gianluca Anastasia Federico Di Giusto Valentina Loria Nadia Aspromonte
author_facet	Luigi Cappannoli Roberto Scacciavillani Giulia Iannaccone Gianluca Anastasia Federico Di Giusto Valentina Loria Nadia Aspromonte
author_sort	Luigi Cappannoli
title	2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
title_short	2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
title_full	2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
title_fullStr	2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
title_full_unstemmed	2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
title_sort	2019 novel-coronavirus: cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/ee1065e9e7ef4c3dae9e5b007d6c215f
work_keys_str_mv	AT luigicappannoli 2019novelcoronaviruscardiovascularinsightsaboutriskfactorsmyocardialinjurytherapyandclinicalimplications AT robertoscacciavillani 2019novelcoronaviruscardiovascularinsightsaboutriskfactorsmyocardialinjurytherapyandclinicalimplications AT giuliaiannaccone 2019novelcoronaviruscardiovascularinsightsaboutriskfactorsmyocardialinjurytherapyandclinicalimplications AT gianlucaanastasia 2019novelcoronaviruscardiovascularinsightsaboutriskfactorsmyocardialinjurytherapyandclinicalimplications AT federicodigiusto 2019novelcoronaviruscardiovascularinsightsaboutriskfactorsmyocardialinjurytherapyandclinicalimplications AT valentinaloria 2019novelcoronaviruscardiovascularinsightsaboutriskfactorsmyocardialinjurytherapyandclinicalimplications AT nadiaaspromonte 2019novelcoronaviruscardiovascularinsightsaboutriskfactorsmyocardialinjurytherapyandclinicalimplications
_version_	1718391523818602496

2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications

Ejemplares similares